ECMO in severe hypoxemia post liver transplant for hepatopulmonary syndrome

Int J Artif Organs. 2024 Nov;47(11):858-861. doi: 10.1177/03913988241274252. Epub 2024 Sep 2.

Abstract

Hepatopulmonary syndrome (HPS) poses a significant challenge in liver transplant patients, affecting between 10% and 30% of candidates. Historically, HPS was considered a contraindication for liver transplantation due to its association with high mortality rates. However, recent studies have shown improvements in pulmonary function post-transplant, leading to the inclusion of these patients as candidates. Despite this progress, approximately one-fifth of liver transplant recipients develop severe postoperative hypoxia, further complicating their clinical course and contributing to increased mortality. The management of post-transplant HPS involves various strategies, including extracorporeal membrane oxygenation (ECMO), although its use remains infrequently reported. Theoretical models suggest that oxygenation typically improves within 10 days post-transplant, while resolution of HPS may take 6-12 months, making ECMO an attractive possibility as a bridge to recovery in this population. We present a case were ECMO was used in this context.

Keywords: Hepatopulmonary syndrome; extracorporeal membrane oxygenation; hypoxia; liver transplantation; respiratory insufficiency.

Publication types

  • Case Reports

MeSH terms

  • Extracorporeal Membrane Oxygenation*
  • Female
  • Hepatopulmonary Syndrome* / etiology
  • Hepatopulmonary Syndrome* / physiopathology
  • Hepatopulmonary Syndrome* / surgery
  • Hepatopulmonary Syndrome* / therapy
  • Humans
  • Hypoxia* / etiology
  • Hypoxia* / therapy
  • Liver Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Postoperative Complications / etiology
  • Postoperative Complications / therapy
  • Treatment Outcome